Ajanta Pharma Limited (AJANTPHARM) - Total Liabilities
Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) has total liabilities worth Rs13.57 Billion INR (≈ $146.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Ajanta Pharma Limited long-term investment allocation to see how much of total assets are deployed in long-term investments.
Ajanta Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see AJANTPHARM current and non-current assets.
Ajanta Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Ajanta Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Nexstar Broadcasting Group Inc
NASDAQ:NXST
|
USA | $15.47 Billion |
|
Fujian Wanchen Biotechnology Co. Ltd
SHE:300972
|
China | CN¥7.34 Billion |
|
Celanese Corporation
NYSE:CE
|
USA | $16.82 Billion |
|
Crocs Inc
NASDAQ:CROX
|
USA | $2.92 Billion |
|
SIG Combibloc Group AG
SW:SIGN
|
Switzerland | CHF4.41 Billion |
|
Guangzhou Shiyuan Electronic Technology Co Ltd
SHE:002841
|
China | CN¥14.36 Billion |
|
TAL Education Group
NYSE:TAL
|
USA | $2.69 Billion |
|
KEI Industries Limited
NSE:KEI
|
India | Rs18.20 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Ajanta Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Ajanta Pharma Limited's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ajanta Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ajanta Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Ajanta Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs12.25 Billion ≈ $132.44 Million |
+14.34% |
| 2024-03-31 | Rs10.71 Billion ≈ $115.83 Million |
-17.04% |
| 2023-03-31 | Rs12.91 Billion ≈ $139.62 Million |
+63.17% |
| 2022-03-31 | Rs7.91 Billion ≈ $85.57 Million |
+1.04% |
| 2021-03-31 | Rs7.83 Billion ≈ $84.69 Million |
+8.79% |
| 2020-03-31 | Rs7.20 Billion ≈ $77.85 Million |
+59.62% |
| 2019-03-31 | Rs4.51 Billion ≈ $48.77 Million |
+10.74% |
| 2018-03-31 | Rs4.07 Billion ≈ $44.04 Million |
+59.68% |
| 2017-03-31 | Rs2.55 Billion ≈ $27.58 Million |
-17.57% |
| 2016-03-31 | Rs3.09 Billion ≈ $33.46 Million |
+1.35% |
| 2015-03-31 | Rs3.05 Billion ≈ $33.01 Million |
-14.26% |
| 2014-03-31 | Rs3.56 Billion ≈ $38.50 Million |
+9.51% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.16 Million |
-7.32% |
| 2012-03-31 | Rs3.51 Billion ≈ $37.94 Million |
+19.58% |
| 2011-03-31 | Rs2.93 Billion ≈ $31.72 Million |
-5.43% |
| 2010-03-31 | Rs3.10 Billion ≈ $33.54 Million |
+1.44% |
| 2009-03-31 | Rs3.06 Billion ≈ $33.07 Million |
+36.04% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+47.15% |
| 2007-03-31 | Rs1.53 Billion ≈ $16.52 Million |
+15.49% |
| 2006-03-31 | Rs1.32 Billion ≈ $14.30 Million |
+11.06% |
| 2005-03-31 | Rs1.19 Billion ≈ $12.88 Million |
-- |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more